Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Denis Poddubnyy, ACR 2021: Efficacy of Ixekizumab in Psoriatic Arthritis with Symptoms of Axial Involvement

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Nov 10th 2021

It was a pleasure to discuss with Prof. Denis Poddubnyy (Charité-Universitätsmedizin Berlin, Berlin, Germany) the post-hoc analysis from sub-populations of the phase 3 SPIRIT-1 (NCT01695239) and SPIRIT-2 (NCT02349295) trials aimed at determining the efficacy of ixekizumab in reducing axial symptoms and improving quality of life in patients with PsA and symptoms of axial involvement.

This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.

The abstract entitled ‘Ixekizumab Efficacy in Patients with Psoriatic Arthritis Presenting with Symptoms Indicative of Axial Involvement’ (ABSTRACT NUMBER: 1347) was presented at the ACR Convergence, 5-9 November.

Questions

  1. What are the manifestations of axial involvement in psoriatic arthritis and what are their prevalence? (0:13)
  2. Could you tell us a little about the efficacy of ixekizumab in psoriatic arthritis and the post-hoc analysis you conducted? (1:02)
  3. What were the findings of the analysis? (2:09)

Disclosures: Prof Poddubnyy has received research support from AbbVie, Eli Lilly, MSD, Novartis, and Pfizer; consulting fees from AbbVie, Biocad, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, MSD, Novartis, Pfizer, Samsung Bioepis, and UCB; and speaker fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, MSD, Novartis, Pfizer, and UCB.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Filmed in coverage of virtual ACR Convergence 2021.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup